In Paris in 1957 metformin, by then called glucophage ('glucose eater'), was studied in trials and shown to lower blood glucose in patients with type 2 diabetes, but not in people without diabetes. Unlike sulfonylureas, metformin did not stimulate insulin release, but increased its peripheral uptake and also reduced the release of glucose from the liver. Metformin had gastrointestinal adverse effects which could be minimised by a 'start low, go slow' approach to dosing.
Also in 1957 an American group published similar results for phenformin (phenylethyl biguanide). Phenformin was energetically marketed worldwide by Ciba-Geigy, but by 1959 an association with lactic acidosis was reported. Unfortunately, this report generated little interest. In contrast, metformin was manufactured by a small French company and, among developed countries, was only the preferred biguanide in France and Scotland.
In the 1970s the number of reports of phenforminrelated lactic acidosis and deaths increased. In 1977 it was removed from the market in the USA and also withdrawn from many other countries. The Australian Drug Evaluation Committee recommended severe restrictions on both phenformin and metformin in spite of the different pharmacokinetics of the two drugs. Phenformin is metabolised by the liver and accumulates in patients with a genetic deficiency of the enzyme cytochrome P450 2D6. Metformin is renally excreted and all serious reports of its association with lactic acidosis and deaths are in overdoses or in people with advanced renal failure. 1 Endocrinologists in France and Scotland, who had considerable experience of using metformin safely, continued to prescribe it extensively. In 1968 2 and 1977 3 Scottish studies comparing metformin with chlorpropamide found that glucose control was the same with both drugs, but patients on metformin had less hypoglycaemia and lost weight, while those on the sulfonylurea gained weight. In spite of similar findings published in leading journals, it took the rest of the world a very long time to reach the same conclusions because of unwarranted fears of lactic acidosis. In 1995 the benefits of metformin were rediscovered in the USA 4 and restrictions were eased in Australia.
Of the many subsequent studies perhaps the most influential has been the UK Prospective Diabetes Study. 5 This was a randomised, multicentre, parallel group trial of 3867 patients over 10 years.
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While prescribers are alert for drug-drug interactions, patients may be more interested to know if they can drink alcohol with their medicine. Graham Vernon reviews some drug interactions that consumers are concerned about, and Helen and John Conaglen discuss some of the drugs which can cause sexual dysfunction.
Many people consume nutritional supplements, but these are not always necessary. Serena Parker, Patrick Hanrahan and Claire Barrett consider the harms and benefits of folate.
Concern about the harmful effects of metformin restricted its use for many years. Gillian Shenfield reflects on how this misunderstanding delayed metformin becoming a first-line drug for type 2 diabetes.
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Full text free online at www.australianprescriber.com VOLUME 36 : NUMBER 2 : APRIL 2013 editoriAL reduced the risks of myocardial infarction and allcause mortality. As a result metformin became the first-choice treatment for obese patients with type 2 diabetes. Later subgroup analyses showed that it had similar vascular protective effects in all patients, but it took another decade for these findings to be translated into official recommendations. In 2012 diabetes experts in the USA and Europe 6 declared that metformin is the drug of first choice for all patients with type 2 diabetes. The Australian National Health and Medical Research Council is considering a similar recommendation.
The story is not yet over. Nephrologists believe metformin is underused in kidney disease. Metformin is now also used to treat polycystic ovary syndrome, gestational diabetes and is showing early promise as a treatment for cancer. Recent meta-analyses controversially suggested that metformin may not prevent macrovascular disease 7 , however the risk of cardiovascular events with metformin may be less than with sulfonylureas 8 .
There are many lessons from this saga:
• it takes a very long time to collect good population efficacy and safety data
• medications can produce more benefits and harms than first claimed
• drugs marketed by large pharmaceutical companies dominate the market 9 and using new drugs with limited, short-term data from restricted trial populations is a risky activity
• wider understanding of pharmacodynamics and pharmacokinetics could prevent the belief that all drugs in a chemical group have the same actions and adverse effects
• the long delay of translating evidence into practice is occurring with other medicines such as aspirin for preventing cardiovascular disease. • some are expensive and could exhaust patients' limited budgets
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• some, in fact, may do no good at all or at least there is minimal evidence they do good
• some patients maintain adverse lifestyle choices because they felt, or wanted to believe,
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